A randomised, double-blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO-524 in dogs with atopic dermatitis

Antinol® Latest Studies

Sorted by recent

What’s better than fun? Double the fun! That’s exactly what 22Fun delivers with its incredible mix of games and opportunities. Whether you’re spinning the reels on slots or trying your hand at a live casino table, 22fun guarantees non-stop entertainment. This platform knows how to keep players smiling with its engaging design and rewarding features. Why just play when you can truly have fun with every bet?

Filter Studies by Smart Tags

Bone & JointCardiovascularCase Study & ProceedingCatDogEAB 277™EfficacyExotic PetImmunologyNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTI

Smart Search

DogSkin

A randomised, double-blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO-524 in dogs with atopic dermatitis

DOI: 10.1111/vde.13193
Authors:
Takeo Nishiyama, Masashi Kusakabe, Ichiro Imanishi, Tadashi Hisano, Teruyasu Fukamachi, Norihito Taguchi, Keita Iyori, Yun-Hsia Hsiao
INTRODUCTION
Polyunsaturated fatty acids (PUFA) can be beneficial in the management of canine atopic dermatitis (cAD). A commercial product PCSO524 containing PUFA has demonstrated anti-inflammatory effects in dogs.
Hypothesis/Objectives:
To evaluate the efficacy of PCSO-524, in combination with oclacitinib in dogs with cAD.
Animals:
Seventeen client-owned dogs with cAD.
Materials and Methods:
A randomised, double-blinded, controlled trial. All dogs were treated with oclacitinib (0.4–0.6mg/kg) twice a day for 14days, then once a day until Day (D)42. They were randomly divided into two groups: PCSO-524 (n=9) and sunflower oil (n=8). Clinical status was assessed by Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI-04) and pruritus Visual Analog Scale (pVAS) at baseline (D0), D14, D28 and D42. Trans epidermal water loss (TEWL) was measured at the same time points.
Results:
CADESI scores decreased significantly after treatment and there was a significant difference between the PCSO-524 and the control group at D28 (p=0.04) and D42 (p=0.03). The PCSO-524 group also demonstrated a significantly decreased pVAS on D28 and D42 (p<0.001 and p<0.001) compared to D0, while significant differences were observed in the control group at D14 and D28 (p<0.01 and p=0.04) and not at D42 (p=0.12). The mean TEWL showed a significant decrease at D28 and D42 in the PCSO-524 group, compared to the control group (p=0.002 and p<0.001).
Conclusions and Clinical Relevance:
The combination of PCSO-524 and oclacitinib may help to alleviate the rebound effect that occurs when tapering down the dosage of oclacitinib, as compared to using oclacitinib alone for the management of cAD.
KEYWORDS:
atopic dermatitis, essential fatty acids, oclacitinib, PCSO-524, rebound effect
. . . VIEW

. . . VIEW

Updated Study Topics

New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted

 

Discover More Studies
Click to see the library